{"id":350378,"date":"2026-11-17T14:42:55","date_gmt":"2026-11-17T09:12:55","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350378"},"modified":"2026-11-17T14:42:55","modified_gmt":"2026-11-17T09:12:55","slug":"pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/","title":{"rendered":"3 Pharmaceuticals Company, Iron Ore Miner and Engineering Consultancy Company Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, NMDC and Engineers India"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Alembic Pharmaceuticals, NMDC and Engineers India: ROE of 11.9% to 22.0% and FY22 to FY26 revenue CAGR of 5.9% to 8.4%. Prices as of 16 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>pharma, iron ore and consultancy stocks<\/strong> to watch are <strong>Alembic Pharmaceuticals<\/strong>, <strong>NMDC<\/strong> and <strong>Engineers India<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>11.9% to 22.0%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 5.9% to 8.4%. Engineers India has the highest return on equity at 22.0%, while Alembic Pharmaceuticals has the fastest revenue growth at 8.4% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Pharma, iron ore and consultancy stocks offer a focused view of a sector where demand keeps widening. Alembic Pharmaceuticals, NMDC and Engineers India cover a pharmaceuticals company, an iron ore miner and an engineering consultancy company.<\/p>\n<p>This list covers three pharma, iron ore and consultancy stocks with complete current figures: Alembic Pharmaceuticals, NMDC and Engineers India. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#What_Are_Pharma_Iron_Ore_and_Consultancy_Stocks\" title=\"What Are Pharma, Iron Ore and Consultancy Stocks?\">What Are Pharma, Iron Ore and Consultancy Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Pharma_Iron_Ore_and_Consultancy_Stocks_at_a_Glance\" title=\"Pharma, Iron Ore and Consultancy Stocks at a Glance\">Pharma, Iron Ore and Consultancy Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Why_Do_Pharma_Iron_Ore_and_Consultancy_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Pharma, Iron Ore and Consultancy Stocks Have a Strong Roadmap in India?\">Why Do Pharma, Iron Ore and Consultancy Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Why_Alembic_Pharmaceuticals_Features_Among_These_Pharma_Iron_Ore_and_Consultancy_Stocks\" title=\"Why Alembic Pharmaceuticals Features Among These Pharma, Iron Ore and Consultancy Stocks\">Why Alembic Pharmaceuticals Features Among These Pharma, Iron Ore and Consultancy Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Why_NMDC_Features_Among_These_Pharma_Iron_Ore_and_Consultancy_Stocks\" title=\"Why NMDC Features Among These Pharma, Iron Ore and Consultancy Stocks\">Why NMDC Features Among These Pharma, Iron Ore and Consultancy Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Why_Engineers_India_Features_Among_These_Pharma_Iron_Ore_and_Consultancy_Stocks\" title=\"Why Engineers India Features Among These Pharma, Iron Ore and Consultancy Stocks\">Why Engineers India Features Among These Pharma, Iron Ore and Consultancy Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Alembic_Pharmaceuticals_vs_NMDC_vs_Engineers_India_on_Key_Financials\" title=\"Alembic Pharmaceuticals vs NMDC vs Engineers India on Key Financials\">Alembic Pharmaceuticals vs NMDC vs Engineers India on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Key_Risks_to_Check_Before_Investing_in_Pharma_Iron_Ore_and_Consultancy_Stocks\" title=\"Key Risks to Check Before Investing in Pharma, Iron Ore and Consultancy Stocks\">Key Risks to Check Before Investing in Pharma, Iron Ore and Consultancy Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Final_Thoughts_on_Pharma_Iron_Ore_and_Consultancy_Stocks\" title=\"Final Thoughts on Pharma, Iron Ore and Consultancy Stocks\">Final Thoughts on Pharma, Iron Ore and Consultancy Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#What_are_pharma_iron_ore_and_consultancy_stocks\" title=\"What are pharma, iron ore and consultancy stocks?\">What are pharma, iron ore and consultancy stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Which_pharma_iron_ore_and_consultancy_stocks_are_covered_in_this_list\" title=\"Which pharma, iron ore and consultancy stocks are covered in this list?\">Which pharma, iron ore and consultancy stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Why_do_pharma_iron_ore_and_consultancy_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do pharma, iron ore and consultancy stocks have a strong future roadmap in India?\">Why do pharma, iron ore and consultancy stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#How_has_Alembic_Pharmaceuticals_performed_financially\" title=\"How has Alembic Pharmaceuticals performed financially?\">How has Alembic Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#How_has_NMDC_performed_financially\" title=\"How has NMDC performed financially?\">How has NMDC performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#How_has_Engineers_India_performed_financially\" title=\"How has Engineers India performed financially?\">How has Engineers India performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#What_risks_should_investors_check_before_buying_pharma_iron_ore_and_consultancy_stocks\" title=\"What risks should investors check before buying pharma, iron ore and consultancy stocks?\">What risks should investors check before buying pharma, iron ore and consultancy stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company-stocks-roadmap-downland-list\/#Is_this_list_of_pharma_iron_ore_and_consultancy_stocks_investment_advice\" title=\"Is this list of pharma, iron ore and consultancy stocks investment advice?\">Is this list of pharma, iron ore and consultancy stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Pharma_Iron_Ore_and_Consultancy_Stocks\"><\/span><strong>What Are Pharma, Iron Ore and Consultancy Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Pharma, iron ore and consultancy stocks<\/strong> are listed companies that make and sell medicines for India and global markets, mine iron ore for steel makers, and provide engineering design and project management services for refineries and plants. Their earnings depend on medicine demand, steel demand and project spending.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Pharma_Iron_Ore_and_Consultancy_Stocks_at_a_Glance\"><\/span><strong>Pharma, Iron Ore and Consultancy Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\">Alembic Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,057.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,914<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.25<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/nmdc\/nmdc-ltd-share-price-today\">NMDC<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">68.92<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">61,921<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.19<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/enginersin\/engineers-india-ltd-share-price-today\">Engineers India<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">312.05<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,096<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a <strong>P\/E<\/strong> below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing pharma, iron ore and consultancy stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Pharma_Iron_Ore_and_Consultancy_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Pharma, Iron Ore and Consultancy Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Pharma, iron ore and consultancy stocks have a strong roadmap in India because wider access to quality medicines, steady steel production and steady project investment in energy and industry keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Pharmaceuticals.<\/strong> Patients need quality medicines.<\/li>\n<li><strong>Iron ore.<\/strong> Steel makers need steady ore supply.<\/li>\n<li><strong>Engineering consultancy.<\/strong> Plants need expert design and management.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Alembic_Pharmaceuticals_Features_Among_These_Pharma_Iron_Ore_and_Consultancy_Stocks\"><\/span><strong>Why Alembic Pharmaceuticals Features Among These Pharma, Iron Ore and Consultancy Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the <strong>pharma, iron ore and consultancy stocks<\/strong> on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.<\/p>\n<p>Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%.<\/p>\n<p>In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a <strong>market capitalisation<\/strong> of Rs 14,914 crore. The stock trades at a <strong>P\/E<\/strong> of 21.6, below the industry P\/E of 35.7.<\/p>\n<p><strong>Roadmap:<\/strong> The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.<\/p>\n<p><strong>What to watch:<\/strong> Follow new approvals in the United States, the pace of complex generic launches and domestic growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_NMDC_Features_Among_These_Pharma_Iron_Ore_and_Consultancy_Stocks\"><\/span><strong>Why NMDC Features Among These Pharma, Iron Ore and Consultancy Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the drug maker, ore miner and project advisor shares on this list, NMDC is a public sector miner and India&#8217;s largest producer of iron ore, with mines in Chhattisgarh and Karnataka, and it also has interests in lithium, diamonds and other minerals.<\/p>\n<p>In the June 2026 quarter, revenue grew 1.5% year on year to Rs 7,143 crore, while net profit rose 1.9% to Rs 2,006 crore. Revenue rose from Rs 26,683 crore in FY22 to Rs 33,559 crore in FY26, a compound annual growth rate of 5.9%.<\/p>\n<p>Net profit grew from Rs 5,538 crore in FY23 to Rs 7,415 crore in FY26, which works out to a compound annual growth rate of 10.2%. The company has a return on equity of 21.9%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 61,921 crore. The stock trades at a P\/E of 8.3, below the industry P\/E of 9.9.<\/p>\n<p><strong>Roadmap:<\/strong> The company plans to raise production capacity to meet the country&#8217;s growing steel demand and has a debt-free balance sheet that supports its mining expansion. Its low-cost iron ore and new mineral projects give it multiple growth options.<\/p>\n<p><strong>What to watch:<\/strong> Follow iron ore volumes and prices and the pace of its expansion and critical mineral projects.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Engineers_India_Features_Among_These_Pharma_Iron_Ore_and_Consultancy_Stocks\"><\/span><strong>Why Engineers India Features Among These Pharma, Iron Ore and Consultancy Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Engineers India is a public sector engineering consultancy and project company that provides design, project management and construction services to oil, gas, petrochemical, fertiliser and infrastructure clients.<\/p>\n<p>The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P\/E of 19.2, below the industry P\/E of 22.7.<\/p>\n<p>Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%.<\/p>\n<p><strong>Roadmap:<\/strong> The company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.<\/p>\n<p><strong>What to watch:<\/strong> Monitor order inflow from refinery and petrochemical projects and execution of existing mandates.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharmaceuticals_vs_NMDC_vs_Engineers_India_on_Key_Financials\"><\/span><strong>Alembic Pharmaceuticals vs NMDC vs Engineers India on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three pharma, iron ore and consultancy stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Alembic Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,356<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,399<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">671<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">NMDC<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26,683<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33,559<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,415<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Engineers India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,043<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,123<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">692<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Engineers India posts the highest return on equity in this group at 22.0%. NMDC has the largest FY26 revenue at Rs 33,559 crore, and Alembic Pharmaceuticals shows the fastest revenue growth with a 8.4% compound annual rate. A useful habit with pharma, iron ore and consultancy stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Pharma_Iron_Ore_and_Consultancy_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Pharma, Iron Ore and Consultancy Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these <strong>pharma, iron ore and consultancy stocks<\/strong>, the main points are: Long-term drug maker, ore miner and project advisor shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Commodity prices.<\/strong> Selling prices follow global and domestic markets.<\/li>\n<li><strong>Order timing.<\/strong> Project awards can shift between periods.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter pharma, iron ore and consultancy stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Pharma_Iron_Ore_and_Consultancy_Stocks\"><\/span><strong>Final Thoughts on Pharma, Iron Ore and Consultancy Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Pharma, iron ore and consultancy stocks reward patient research into demand, execution and financial strength. Alembic Pharmaceuticals, NMDC and Engineers India each have a clear plan to grow. Based on the 16 November 2026 close, Alembic Pharmaceuticals trades at Rs 1,057.1, NMDC at Rs 68.92 and Engineers India at Rs 312.05.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track pharma, iron ore and consultancy stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_pharma_iron_ore_and_consultancy_stocks\"><\/span><strong>What are pharma, iron ore and consultancy stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>Pharma, iron ore and consultancy stocks<\/strong> are listed companies that make and sell medicines for India and global markets, mine iron ore for steel makers, and provide engineering design and project management services for refineries and plants. Their earnings depend on medicine demand, steel demand and project spending. This list looks at three of them, Alembic Pharmaceuticals, NMDC and Engineers India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_iron_ore_and_consultancy_stocks_are_covered_in_this_list\"><\/span><strong>Which pharma, iron ore and consultancy stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Alembic Pharmaceuticals, NMDC and Engineers India. Based on the 16 November 2026 close, Alembic Pharmaceuticals traded at Rs 1,057.1, NMDC at Rs 68.92 and Engineers India at Rs 312.05. Their return on equity ranges from <strong>11.9% to 22.0%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 5.9% to 8.4%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_pharma_iron_ore_and_consultancy_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do pharma, iron ore and consultancy stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Pharma, iron ore and consultancy stocks have a strong roadmap in India because wider access to quality medicines, steady steel production and steady project investment in energy and industry keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need quality medicines. Iron ore. Steel makers need steady ore supply. Engineering consultancy. Plants need expert design and management. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Alembic_Pharmaceuticals_performed_financially\"><\/span><strong>How has Alembic Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P\/E of 21.6, below the industry P\/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_NMDC_performed_financially\"><\/span><strong>How has NMDC performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 26,683 crore in FY22 to Rs 33,559 crore in FY26, a compound annual growth rate of 5.9%. Net profit grew from Rs 5,538 crore in FY23 to Rs 7,415 crore in FY26, which works out to a compound annual growth rate of 10.2%. In the June 2026 quarter, revenue grew 1.5% year on year to Rs 7,143 crore, while net profit rose 1.9% to Rs 2,006 crore. The company has a return on equity of 21.9%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 61,921 crore. The stock trades at a P\/E of 8.3, below the industry P\/E of 9.9. Looking ahead, the company plans to raise production capacity to meet the country&#8217;s growing steel demand and has a debt-free balance sheet that supports its mining expansion. Its low-cost iron ore and new mineral projects give it multiple growth options.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Engineers_India_performed_financially\"><\/span><strong>How has Engineers India performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P\/E of 19.2, below the industry P\/E of 22.7. Looking ahead, the company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_pharma_iron_ore_and_consultancy_stocks\"><\/span><strong>What risks should investors check before buying pharma, iron ore and consultancy stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying pharma, iron ore and consultancy stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Commodity prices. Selling prices follow global and domestic markets. Order timing. Project awards can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_pharma_iron_ore_and_consultancy_stocks_investment_advice\"><\/span><strong>Is this list of pharma, iron ore and consultancy stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are pharma, iron ore and consultancy stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pharma, iron ore and consultancy stocks are listed companies that make and sell medicines for India and global markets, mine iron ore for steel makers, and provide engineering design and project management services for refineries and plants. Their earnings depend on medicine demand, steel demand and project spending. This list looks at three of them, Alembic Pharmaceuticals, NMDC and Engineers India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma, iron ore and consultancy stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Alembic Pharmaceuticals, NMDC and Engineers India. Based on the 16 November 2026 close, Alembic Pharmaceuticals traded at Rs 1,057.1, NMDC at Rs 68.92 and Engineers India at Rs 312.05. Their return on equity ranges from 11.9% to 22.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.9% to 8.4%.\"}},{\"@type\":\"Question\",\"name\":\"Why do pharma, iron ore and consultancy stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pharma, iron ore and consultancy stocks have a strong roadmap in India because wider access to quality medicines, steady steel production and steady project investment in energy and industry keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need quality medicines. Iron ore. Steel makers need steady ore supply. Engineering consultancy. Plants need expert design and management. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Alembic Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P\/E of 21.6, below the industry P\/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.\"}},{\"@type\":\"Question\",\"name\":\"How has NMDC performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 26,683 crore in FY22 to Rs 33,559 crore in FY26, a compound annual growth rate of 5.9%. Net profit grew from Rs 5,538 crore in FY23 to Rs 7,415 crore in FY26, which works out to a compound annual growth rate of 10.2%. In the June 2026 quarter, revenue grew 1.5% year on year to Rs 7,143 crore, while net profit rose 1.9% to Rs 2,006 crore. The company has a return on equity of 21.9%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 61,921 crore. The stock trades at a P\/E of 8.3, below the industry P\/E of 9.9. Looking ahead, the company plans to raise production capacity to meet the country's growing steel demand and has a debt-free balance sheet that supports its mining expansion. Its low-cost iron ore and new mineral projects give it multiple growth options.\"}},{\"@type\":\"Question\",\"name\":\"How has Engineers India performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P\/E of 19.2, below the industry P\/E of 22.7. Looking ahead, the company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying pharma, iron ore and consultancy stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying pharma, iron ore and consultancy stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Commodity prices. Selling prices follow global and domestic markets. Order timing. Project awards can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of pharma, iron ore and consultancy stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pharma, Iron Ore and Consultancy Stocks with a strong future roadmap: Alembic Pharmaceuticals, NMDC and Engineers India. Compare price, valuation, return on equity and revenue growth as of 16 November 2026.<\/p>\n","protected":false},"author":34,"featured_media":350375,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[10050,3803,22657,5971,22792,24955,24957,8607,24956],"class_list":["post-350378","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-alembic-pharmaceuticals","tag-best-stocks","tag-drug-maker","tag-engineers-india","tag-formulations","tag-iron-ore-and-consultancy-stocks","tag-mining-and-design-services-stocks","tag-nmdc","tag-ore-miner-and-project-advisor-shares"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350375"],"rank_math_title":["Pharma, Iron Ore and Engineering Consultancy Stocks"],"rank_math_description":["Compare 3 pharma, iron ore and consultancy stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 16 Nov 2026."],"rank_math_focus_keyword":["pharma, iron ore and consultancy stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-pharmaceuticals-company-iron-ore-miner-and-engineering-consultancy-company.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350378"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350378\/revisions"}],"predecessor-version":[{"id":350379,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350378\/revisions\/350379"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350375"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}